Previous 10 | Next 10 |
- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially affect overall MOMENTUM timelines - - Publications highlighting durability, safety, and efficacy data for momelotinib planned throughout 2020 ...
Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call Canada NewsWire VANCOUVER, Feb. 26, 2020 VANCOUVER , Feb. 26, 2020 /CNW/ - Sierra Oncology, Inc...
-"Building MOMENTUM for Patients with Myelofibrosis" scheduled for 10:00 a.m. ET on March 4, 2020 - VANCOUVER , Feb. 25, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, ...
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead Canada NewsWire VANCOUVER, Feb. 6, 2020 VANCOUVER , Feb. 6, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commerc...
Nano cap Sierra Oncology (NASDAQ: SRRA ) slumps 16% premarket on increased volume in reaction to its planned 1:40 reverse spli t of its common stock effective after the close today. Post-split trading will commence tomorrow, January 23, at the open. More news on: Sierra Oncolo...
Sierra Oncology Announces Reverse Stock Split Canada NewsWire VANCOUVER, Jan. 22, 2020 - Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement ...
These 4 Penny Stocks Can Be Bought For Under $2 Right Now; But Are They A “Buy”? Investing in penny stocks can often prove to be one of the best ways of generating massive gains in a short time. Moreover, penny stocks are the cheapest stocks in the market so it’s possibl...
These Penny Stocks Have Taken Off This Quarter; Will They Head Higher? Investing in penny stocks has proven to be one of the best ways of making a fortune in the stock market and over the years plenty of investors have managed to do exactly that. However, identifying such penny stocks is n...
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Canada NewsWire VANCOUVER, Dec. 7, 2019 - New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefit...
Amedisys (NASDAQ: AMED ) initiated with Market Perform rating and $170 (3% upside) price target at BMO. More news on: Amedisys, Inc., Athenex, Inc., Gossamer Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...